AU2022228575C1 - Compositions including sbi adjuvants and methods of use thereof - Google Patents

Compositions including sbi adjuvants and methods of use thereof

Info

Publication number
AU2022228575C1
AU2022228575C1 AU2022228575A AU2022228575A AU2022228575C1 AU 2022228575 C1 AU2022228575 C1 AU 2022228575C1 AU 2022228575 A AU2022228575 A AU 2022228575A AU 2022228575 A AU2022228575 A AU 2022228575A AU 2022228575 C1 AU2022228575 C1 AU 2022228575C1
Authority
AU
Australia
Prior art keywords
antigen
fusion
fragment
polynucleotide
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2022228575A
Other languages
English (en)
Other versions
AU2022228575B2 (en
AU2022228575A1 (en
Inventor
Kyle BACKMAN
Nikhil Dhar
Nikolai EROSHENKO
Taylor GILL
Kemo JAMMEH
Marianna KEAVENEY
Justin Quinn
Hannu Rajaniemi
Everett WEBSTER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helix Nanotechnologies Inc
Original Assignee
Helix Nanotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helix Nanotechnologies Inc filed Critical Helix Nanotechnologies Inc
Publication of AU2022228575A1 publication Critical patent/AU2022228575A1/en
Assigned to HELIX NANOTECHNOLOGIES INC reassignment HELIX NANOTECHNOLOGIES INC Amend patent request/document other than specification (104) Assignors: HELIX NANOTECHNOLOGIES, INC.
Publication of AU2022228575B2 publication Critical patent/AU2022228575B2/en
Priority to AU2025205053A priority Critical patent/AU2025205053A1/en
Application granted granted Critical
Publication of AU2022228575C1 publication Critical patent/AU2022228575C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2022228575A 2021-03-04 2022-03-03 Compositions including sbi adjuvants and methods of use thereof Active AU2022228575C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025205053A AU2025205053A1 (en) 2021-03-04 2025-07-02 Compositions including Sbi adjuvants and methods of use thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163156860P 2021-03-04 2021-03-04
US63/156,860 2021-03-04
PCT/US2022/018610 WO2022187424A1 (en) 2021-03-04 2022-03-03 Compositions including sbi adjuvants and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025205053A Division AU2025205053A1 (en) 2021-03-04 2025-07-02 Compositions including Sbi adjuvants and methods of use thereof

Publications (3)

Publication Number Publication Date
AU2022228575A1 AU2022228575A1 (en) 2023-10-12
AU2022228575B2 AU2022228575B2 (en) 2025-04-03
AU2022228575C1 true AU2022228575C1 (en) 2025-10-09

Family

ID=80820175

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2022228575A Active AU2022228575C1 (en) 2021-03-04 2022-03-03 Compositions including sbi adjuvants and methods of use thereof
AU2025205053A Pending AU2025205053A1 (en) 2021-03-04 2025-07-02 Compositions including Sbi adjuvants and methods of use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025205053A Pending AU2025205053A1 (en) 2021-03-04 2025-07-02 Compositions including Sbi adjuvants and methods of use thereof

Country Status (11)

Country Link
US (3) US11771758B2 (https=)
EP (1) EP4301404A1 (https=)
JP (2) JP2024508683A (https=)
KR (1) KR20230154048A (https=)
CN (2) CN116916950A (https=)
AU (2) AU2022228575C1 (https=)
BR (1) BR112023017749A2 (https=)
CA (1) CA3211083A1 (https=)
IL (2) IL320523A (https=)
MX (1) MX2023009995A (https=)
WO (1) WO2022187424A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019060631A1 (en) * 2017-09-20 2019-03-28 Helix Nanotechnologies, Inc. EXPRESSION SYSTEMS THAT FACILITATE THE DELIVERY OF NUCLEIC ACIDS AND METHODS OF USE
CA3211083A1 (en) 2021-03-04 2022-09-09 Kyle BACKMAN Compositions including sbi adjuvants and methods of use thereof
WO2025137486A1 (en) 2023-12-22 2025-06-26 Helix Nanotechnologies Inc Cap compounds and rnas comprising the same
US20250270299A1 (en) * 2024-01-31 2025-08-28 Helix Nanotechnologies Inc Methods of using compositions comprising sbi domains
WO2025166067A1 (en) 2024-01-31 2025-08-07 Helix Nanotechnologies, Inc. Sars-cov-2 vaccine compositions and methods
WO2026015884A1 (en) 2024-07-11 2026-01-15 Helix Nanotechnologies Inc Compositions comprising ire-1 binding sequences and uses thereof
WO2026084768A1 (en) 2024-10-16 2026-04-23 Helix Nanotechnologies Inc Helper proteins for increased secretion

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6485904B1 (en) * 1997-06-23 2002-11-26 Pfizer, Inc. DNA encoding a plasminogen activating protein
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
AU2002303135A1 (en) * 2001-03-13 2002-09-24 Corixa Corporation Heterologous fusion protein constructs comprising a leishmania antigen
GB0605735D0 (en) * 2006-03-22 2006-05-03 Immunobiology Ltd Composition and method for mediating an immune response
GB0610776D0 (en) 2006-05-31 2006-07-12 Univ Bath Novel applications for staphylococcus aureus Sbi protein
GB201016403D0 (en) 2010-09-29 2010-11-10 Bath Ventures Novel interaction between staphylococcus aureus Sbi and C3d protiens
RU2016110800A (ru) * 2013-09-25 2017-10-30 Пронутриа Биосайенсис, Инк. Составы и композиции для поддержания и увеличения мышечной массы, силы и результативности, и способы их производства и использования
GB201619965D0 (en) 2016-11-25 2017-01-11 Univ Of Bath The Immunogenic compositions comprising sbi protein and uses thereof
JP6792847B2 (ja) * 2016-12-27 2020-12-02 国立大学法人 東京大学 ｍＲＮＡの機能化方法
MA54192A (fr) * 2018-11-07 2021-09-15 Modernatx Inc Vaccins à arn contre le cancer
AU2020321021A1 (en) * 2019-07-30 2022-03-10 Verndari, Inc. Virus-like particle vaccines
US20230302116A1 (en) * 2020-05-06 2023-09-28 Ginkgo Bioworks, Inc. VARIANT SARS-CoV-2 PROTEINS AND USES THEREOF
CA3211083A1 (en) 2021-03-04 2022-09-09 Kyle BACKMAN Compositions including sbi adjuvants and methods of use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Almansoor (Development of vaccine conjugates based on Dengue virus using staphylococcal immune evasion protein, 2017, p. 1-66). *
YANG JINGYUN ET AL: "A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity", NATURE, vol. 586, no. 7830, 29 July 2020 (2020-07-29), pages 572 - 577 *
YANG YI ET AL: "Utilization of Staphylococcal Immune Evasion Protein Sbi as a Novel Vaccine Adjuvant", FRONTIERS IN IMMUNOLOGY, vol. 9, 11 January 2019 (2019-01-11), XP055923724, DOI: 10.3389/fimmu.2018.03139 *

Also Published As

Publication number Publication date
CN119161490A (zh) 2024-12-20
KR20230154048A (ko) 2023-11-07
NZ804057A (en) 2025-07-25
JP2025026590A (ja) 2025-02-21
AU2022228575B2 (en) 2025-04-03
EP4301404A1 (en) 2024-01-10
US12343392B2 (en) 2025-07-01
US11771758B2 (en) 2023-10-03
CN116916950A (zh) 2023-10-20
IL305333B1 (en) 2025-06-01
US20240082388A1 (en) 2024-03-14
JP2024508683A (ja) 2024-02-28
AU2022228575A1 (en) 2023-10-12
IL305333B2 (en) 2025-10-01
BR112023017749A2 (pt) 2023-10-03
US20220362373A1 (en) 2022-11-17
AU2025205053A1 (en) 2025-07-24
IL320523A (en) 2025-06-01
IL305333A (en) 2023-10-01
CA3211083A1 (en) 2022-09-09
MX2023009995A (es) 2023-11-22
US20260061048A1 (en) 2026-03-05
WO2022187424A1 (en) 2022-09-09

Similar Documents

Publication Publication Date Title
AU2022228575C1 (en) Compositions including sbi adjuvants and methods of use thereof
Powell et al. A single immunization with spike-functionalized ferritin vaccines elicits neutralizing antibody responses against SARS-CoV-2 in mice
US11969467B2 (en) Nucleic acid vaccine against the SARS-CoV-2 coronavirus
CN113461787A (zh) 一种重组新型冠状病毒s-rbd三聚体蛋白、其制备方法和应用
US12551551B2 (en) Compositions comprising α-factor prepro sequence and uses thereof
WO2022090679A1 (en) Coronavirus polypeptide
US20240228549A1 (en) Prefusion-stabilized lassa virus glycoprotein complex and its use
WO2022010813A2 (en) Enhancing immune responses through targeted antigen expression
US8956620B2 (en) Anti-HIV vaccine constructed based on amino acid mutations in attenuated live EIAV vaccine
RU2850338C2 (ru) Композиции, содержащие адъюванты sbi, и способы их применения
HK40120523A (zh) 包含sbi佐剂的组合物及其使用方法
US20250270299A1 (en) Methods of using compositions comprising sbi domains
US20240131148A1 (en) Immunogenic compositions
Wardiana et al. Immunogenicity evaluation of an Alum-adjuvanted recombinant prefusion RBD-Fd SARS-CoV-2 protein subunit produced in Glycoengineered Pichia pastoris
US20230210981A1 (en) Coronavirus disease 2019 (covid-19) combination vaccine
WO2026030724A1 (en) Sars-cov-2 vaccine
CN119264229A (zh) 基于SARS-CoV-2的不同奥密克戎变异型的S蛋白的疫苗和组合物
WO2025166067A1 (en) Sars-cov-2 vaccine compositions and methods
CN117957017A (zh) 包含重组重叠肽和天然蛋白质的疫苗制剂

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: HELIX NANOTECHNOLOGIES INC

Free format text: FORMER NAME(S): HELIX NANOTECHNOLOGIES, INC.

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 02 JUL 2025

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 02 JUL 2025

FGA Letters patent sealed or granted (standard patent)